Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/simplifying-treatment-and-reducing-recurrence-for-patients-with-early-oCZBwGnRBe
- Publisher
- American Medical Association
- Copyright
- Copyright 2018 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2018.4656
- pmid
- 29800998
- Publisher site
- See Article on Publisher Site
Abstract
Opinion EDITORIAL Simplifying Treatment and Reducing Recurrence for Patients With Early-Stage Bladder Cancer Samuel D. Kaffenberger, MD; David C. Miller, MD, MPH; Matthew E. Nielsen, MD, MS The burden of bladder cancer in the United States is large and time to recurrence of bladder cancer. In the intention-to-treat population, cancer recurrence within 4 years was significantly expanding with the aging population; the annual incidence has increased from approximately 50 000 cases per year in the lower in the group with immediate postoperative instillation of 1990s to nearly 80 000 new intravesical gemcitabine (n=67; 4-year estimated recurrence rate, cases projected for 2017. 35%) than in the placebo group (n=91; recurrence rate, 47%; haz- Related article page 1880 Non–muscle-invasive blad- ard ratio, 0.66; 95% CI, 0.48-0.90). In the prespecified target der cancers represent approximately 75% of all incident cases, population (n = 215 with low-grade noninvasive bladder cancer), of which the majority are low-grade tumors. Low-grade blad- cancer recurrence within 4 years also was significantly lower der cancers frequently recur but rarely result in cancer pro- (gemcitabine group: n=34; 4-year estimated rate, 34% placebo gression or death. In addition to being the most expensive can- group: n=59; 4-year estimated rate, 54%;
Journal
JAMA – American Medical Association
Published: May 8, 2018